Gene Page:ASXL2
Summary?
| GeneID | 55252 |
| Symbol | ASXL2 |
| Synonyms | ASXH2 |
| Description | additional sex combs like 2, transcriptional regulator |
| Reference | MIM:612991|HGNC:HGNC:23805|Ensembl:ENSG00000143970|HPRD:10676|Vega:OTTHUMG00000152176 |
| Gene type | protein-coding |
| Map location | 2p24.1 |
| Pascal p-value | 0.032 |
| Sherlock p-value | 0.674 |
| eGene | Nucleus accumbens basal ganglia Myers' cis & trans |
Gene in Data Sources
| Gene set name | Method of gene set | Description | Info |
|---|---|---|---|
| CV:PGCnp | Genome-wide Association Study | GWAS |
Section I. Genetics and epigenetics annotation
eQTL annotation
eQTL annotation| SNP ID | Chromosome | Position | eGene | Gene Entrez ID | pvalue | qvalue | TSS distance | eQTL type |
|---|---|---|---|---|---|---|---|---|
| rs310586 | chr7 | 150893628 | ASXL2 | 55252 | 0.15 | trans |
Section II. Transcriptome annotation
General gene expression (GTEx)
Gene expression of temporal and spatial changes (BrainSpan)
Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
Top co-expressed genes in brain regions
| Top 10 positively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| CHTF18 | 0.90 | 0.89 |
| MICAL1 | 0.90 | 0.87 |
| HEXDC | 0.89 | 0.88 |
| LRRC45 | 0.88 | 0.87 |
| CDK5RAP3 | 0.88 | 0.85 |
| CNTROB | 0.88 | 0.89 |
| LEPRE1 | 0.87 | 0.86 |
| AC145098.2 | 0.87 | 0.85 |
| SUV420H2 | 0.87 | 0.88 |
| WDR85 | 0.87 | 0.82 |
| Top 10 negatively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| AF347015.31 | -0.64 | -0.78 |
| AF347015.27 | -0.64 | -0.77 |
| MT-CO2 | -0.63 | -0.79 |
| C5orf53 | -0.63 | -0.70 |
| AF347015.33 | -0.62 | -0.77 |
| MT-CYB | -0.61 | -0.76 |
| AF347015.8 | -0.60 | -0.78 |
| CA4 | -0.59 | -0.66 |
| HLA-F | -0.59 | -0.64 |
| S100B | -0.58 | -0.68 |
Section V. Pathway annotation
| Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
|---|---|---|---|
| OSMAN BLADDER CANCER DN | 406 | 230 | All SZGR 2.0 genes in this pathway |
| TAKEDA TARGETS OF NUP98 HOXA9 FUSION 16D DN | 143 | 83 | All SZGR 2.0 genes in this pathway |
| MAYBURD RESPONSE TO L663536 UP | 29 | 18 | All SZGR 2.0 genes in this pathway |
| RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED UP | 633 | 376 | All SZGR 2.0 genes in this pathway |
| WEI MIR34A TARGETS | 148 | 97 | All SZGR 2.0 genes in this pathway |
| RICKMAN TUMOR DIFFERENTIATED WELL VS MODERATELY UP | 109 | 69 | All SZGR 2.0 genes in this pathway |
| REN ALVEOLAR RHABDOMYOSARCOMA UP | 98 | 64 | All SZGR 2.0 genes in this pathway |
| IVANOVA HEMATOPOIESIS STEM CELL LONG TERM | 302 | 191 | All SZGR 2.0 genes in this pathway |
| KANG DOXORUBICIN RESISTANCE DN | 19 | 8 | All SZGR 2.0 genes in this pathway |
| IVANOVA HEMATOPOIESIS STEM CELL AND PROGENITOR | 681 | 420 | All SZGR 2.0 genes in this pathway |
| ZHENG BOUND BY FOXP3 | 491 | 310 | All SZGR 2.0 genes in this pathway |
| ZHENG FOXP3 TARGETS IN THYMUS UP | 196 | 137 | All SZGR 2.0 genes in this pathway |
| ACEVEDO肝癌了 | 973 | 570 | All SZGR 2.0 genes in this pathway |
| PILON KLF1 TARGETS UP | 504 | 321 | All SZGR 2.0 genes in this pathway |
| JOHNSTONE PARVB TARGETS 2 UP | 140 | 94 | All SZGR 2.0 genes in this pathway |
| JOHNSTONE PARVB TARGETS 3 UP | 430 | 288 | All SZGR 2.0 genes in this pathway |
| PURBEY TARGETS OF CTBP1 NOT SATB1 DN | 448 | 282 | All SZGR 2.0 genes in this pathway |